Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639664 | 0.92 | GRM5 (0.53) | GRM5USP2SMN1; SMN2CYP1A2ADORA1 | |
| SCHEMBL3639663 | 0.92 | GRM5 (0.53) | GRM5USP2SMN1; SMN2CYP1A2ADORA1 | |
| SCHEMBL29915439 | 0.80 | GRM5 (0.48) | GRM5USP2SMN1; SMN2 | |
| SCHEMBL512793 | 0.80 | GRM5 (0.53) | GRM5USP2SMN1; SMN2ADORA1ESR2 | |
| SCHEMBL99227 | 0.80 | GRM5 (0.53) | GRM5USP2SMN1; SMN2CYP1A2ADORA1 | |
| SCHEMBL515146 | 0.79 | GRM5 (0.42) | GRM5CYP1A2CYP3A4 | |
| SCHEMBL29915493 | 0.79 | GRM5 (0.41) | GRM5USP2SMN1; SMN2ADORA1ESR2 | |
| SCHEMBL29915293 | 0.77 | GRM5 (0.40) | GRM5 | |
| SCHEMBL3644186 | 0.76 | GRM5 (0.51) | GRM5USP2SMN1; SMN2CYP1A2ADORA1 | |
| SCHEMBL3639566 | 0.76 | GRM5 (1.00) | GRM5CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
| EP-2178858-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2178858-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009015897-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | GRM5 2/4885USP2 3153/4885SMN1; SMN2 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.